Alpha-1-proteinase inhibitor
- Generic Name
- Alpha-1-proteinase inhibitor
- Brand Names
- Aralast, Glassia, Prolastin, Prolastin-C, Respreeza, Zemaira
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9041-92-3
- Unique Ingredient Identifier
- F43I396OIS
- Background
Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.
- Indication
For chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.
- Associated Conditions
- Emphysema
- Associated Therapies
- Augmentation, Maintenance therapy
Neonatal Screening for Metabolic and Endocrine Disorders
Neonatal screening in Germany, expanded since 2005 with tandem mass spectrometry, aims for early detection and treatment of congenital metabolic and endocrine diseases. It's a preventive measure, covering a wide range of diseases, with high specificity and sensitivity. The program's success relies on early screening, flawless organization, and rapid treatment initiation.
Establishment and characterization of mouse metabolic dysfunction-associated ...
Study establishes MASH-HCC organoids using CDAHFD-fed mice, finding multi-biotics enhance Lenvatinib sensitivity but not prevent resistance. RNA-seq identifies 30 DEGs, including Slc5a8, Vnn3, and Mcm5, linked to metabolic and immune pathways. Enriched pathways like NF-κB and EMT suggest multi-biotics' role in modulating drug response, with potential for adjunct therapy in HCC.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath